BIOV: Bio-View Ltd - Summary | Jitta

Bio-View Ltd

ISR:BIOV

Price
₪0.16
Loss Chance
57.9%
1.58JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
269 / 421
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (9)
Recent Business Performance (19)
Financial Strength (43)
Return to Shareholders (7)
Competitive Advantage (24)
Jitta Signs
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 78.51% in the last quarter (yoy)
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
1.58
100.00%
2.84
95.01%
Health Care Equipment
2.49
100.00%
6.53
197.42%
0.77
100.00%
COMPANY DESCRIPTION
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company’s products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an automated imaging system that supports multiple applications; Encore, an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation that streamlines review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was incorporated in 1998 and is headquartered in Rehovot, Israel.